Submit Deal

Announced

4 Dec 2023

Completed

29 Jan 2024

Oxford Biomedica completed the acquisition of ABL Europe from Institut Mérieux for €15m.

Synopsis

Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, completed the acquisition of ABL Europe, a cell and gene therapy company, from Institut Mérieux, a microbiology company, for €15m.

Principals

target

Abl Europe

bidder

Oxford Biomedica

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Bidder Team (12)

alexander goodman

Associate at Covington & Burling

Lawyer

bidder

Deals

£ 13 M

Total Value

sibel yilmaz

Partner at Covington & Burling

Lawyer

bidder

Deals

£ 1.42 B

Total Value

davide salvi

Consilium Strategic Communications

PR Consultant

bidder

Deals

£ 328 M

Total Value

stuart paynter

CFO at OXFORD BIOMEDICA

Manager

bidder

Deals

£ 77 M

Total Value

frank mathias

CEO at OXFORD BIOMEDICA

Manager

bidder

Deal

£ 13 M

Total Value

oliver hodgkiss

Associate at Covington & Burling

Lawyer

bidder

Deals

£ 13 M

Total Value

rebecca wright

Associate at Covington & Burling

Lawyer

bidder

Deal

£ 13 M

Total Value

ben land-maycock

Special Counsel at Covington & Burling

Lawyer

bidder

Deals

£ 717 M

Total Value

guy dingley

Partner at Covington & Burling

Lawyer

bidder

Deals

£ 5.01 B

Total Value

matthew neal

Partner at Consilium Strategic Communications

PR Consultant

bidder

Deals

£ 2.26 B

Total Value

sophia bolhassan

Head of Investor Relations at OXFORD BIOMEDICA

Manager

bidder

Deals

£ 77 M

Total Value

mary-jane elliott

Managing Partner at Consilium Strategic Communications

PR Consultant

bidder

Deals

£ 10.38 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy